Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2018

View Archived Issues

ApoE has role in birth of neurons in adult brain

SciBac's development of SCB-102 for C. difficile infection supported by CARB-X award

Emergent BioSolutions starts phase I study of ZIKV-IG

Researchers develop new rat model of tauopathy with severe cognitive deficits

Asahi Kasei presents preliminary results of SCARLET phase III trial of ART-123

TiumBio presents preclinical data for NBP-604, a new fusion protein for hemophilia

Celtaxsys reports topline results from phase II EMPIRE-CF trial

Aptinyx begins first-in-human study of NYX-458

Spring Bank Pharmaceuticals reports results from third cohort of ACHIEVE study of inarigivir

Ardelyx patents new NHE-3 inhibitors

Jiangsu Tasly Diyi Pharmaceutical describes SGLT2 inhibitors

KURBF discloses new CRLF2 ligands as IL-6 production inhibitors

AMMS discloses CACNA1B blockers

Better base editing

Diabetic fat stem cells are good enough

Study uncovers atrial fibrillation risk variants

Elucidation of the role of the calcium-binding protein NECAB2 in inflammatory pain hypersensitivity

Glaukos enters collaboration with DWTI to develop intraocular products for the treatment of glaucoma

Rice-grown, pre-mixed HIV prevention cocktail

First patient enrolled in phase III study of RPh-201 in NAION

IAVI and Public Health Agency of Canada announce agreement for Lassa fever vaccine development

Researchers discover new risk locus for AD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...